|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
US6846799B1
(en)
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
AU2180500A
(en)
*
|
1998-12-15 |
2000-07-03 |
Warner-Lambert Company |
Use of a mek inhibitor for preventing transplant rejection
|
|
JP2002534381A
(ja)
*
|
1999-01-07 |
2002-10-15 |
ワーナー−ランバート・カンパニー |
Ｍｅｋ阻害剤を用いた抗ウィルス法
|
|
ID30439A
(id)
|
1999-01-13 |
2001-12-06 |
Warner Lambert Co |
Benzoheterosiklus dan penggunaannya sebagai penghambat mek
|
|
CA2349832A1
(en)
|
1999-01-13 |
2000-07-20 |
Warner-Lambert Company |
Benzenesulfonamide derivatives and their use as mek inhibitors
|
|
AU2482800A
(en)
|
1999-01-13 |
2000-08-01 |
Warner-Lambert Company |
Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
|
|
JP2002534515A
(ja)
|
1999-01-13 |
2002-10-15 |
ワーナー−ランバート・カンパニー |
１−複素環置換されたジアリールアミン
|
|
CA2348236A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
|
US6686499B1
(en)
|
1999-04-21 |
2004-02-03 |
Warner-Lambert Company |
Method for making 2-(N-phenylamino)benzoic acids
|
|
WO2000064856A1
(en)
*
|
1999-04-21 |
2000-11-02 |
Warner-Lambert Company |
Method for making 2-(n-phenylamino)benzoic acids
|
|
GB9910579D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910577D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
HUP0202623A3
(en)
*
|
1999-07-16 |
2003-03-28 |
Warner Lambert Co |
Method for treating chronic pain using mek inhibitors
|
|
JP2003527379A
(ja)
*
|
2000-03-15 |
2003-09-16 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
|
|
US7001905B2
(en)
|
2000-03-15 |
2006-02-21 |
Warner-Lambert Company |
Substituted diarylamines as MEK inhibitors
|
|
DE10017480A1
(de)
*
|
2000-04-07 |
2001-10-11 |
Transmit Technologietransfer |
Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
|
|
AU7349801A
(en)
*
|
2000-07-19 |
2002-01-30 |
Warner Lambert Co |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
AP2001002249A0
(en)
*
|
2000-08-25 |
2001-09-30 |
Warner Lambert Co |
Process for making N-ARYL-ANTHRANILIC acids and their derivatives.
|
|
EP1365796A2
(en)
|
2000-09-01 |
2003-12-03 |
Van Andel Institute |
Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
|
|
US7067532B2
(en)
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
|
WO2002036570A1
(en)
|
2000-11-02 |
2002-05-10 |
Astrazeneca Ab |
4-substituted quinolines as antitumor agents
|
|
WO2002076496A1
(en)
*
|
2001-03-22 |
2002-10-03 |
Van Andel Institute |
Anthrax lethal factor inhibits tumor growth and angiogenesis
|
|
IL149462A0
(en)
|
2001-05-09 |
2002-11-10 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
|
DOP2003000556A
(es)
|
2002-01-23 |
2003-10-31 |
Warner Lambert Co |
Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
|
|
BR0307060A
(pt)
|
2002-01-23 |
2004-10-26 |
Warner Lambert Co |
ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
CA2532067C
(en)
|
2003-07-24 |
2010-12-21 |
Stephen Douglas Barrett |
N-methyle-substituted benzamidazoles
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
JP4931419B2
(ja)
|
2003-09-19 |
2012-05-16 |
中外製薬株式会社 |
新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
|
|
KR101013932B1
(ko)
|
2003-10-21 |
2011-02-14 |
워너-램버트 캄파니 엘엘씨 |
Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
KR101190912B1
(ko)
|
2003-11-19 |
2012-10-12 |
어레이 바이오파마 인크. |
Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
AU2004293026B2
(en)
|
2003-11-21 |
2012-01-19 |
Array Biopharma Inc. |
AKT protein kinase inhibitors
|
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
|
MY144232A
(en)
|
2004-07-26 |
2011-08-15 |
Chugai Pharmaceutical Co Ltd |
5-substituted-2-phenylamino benzamides as mek inhibitors
|
|
MX2007001846A
(es)
|
2004-08-17 |
2007-03-28 |
Hoffmann La Roche |
Hidantoinas sustituidas.
|
|
TW200621766A
(en)
|
2004-09-17 |
2006-07-01 |
Hoffmann La Roche |
Substituted hydantoins
|
|
ES2444866T3
(es)
|
2004-10-20 |
2014-02-27 |
Merck Serono Sa |
Derivados de 3-arilamino piridina
|
|
TW200702329A
(en)
|
2005-04-06 |
2007-01-16 |
Chugai Pharmaceutical Co Ltd |
A process for preparing 2,3,4-trifluoro-5-(iodo or bromo)benzoic acid
|
|
TWI441637B
(zh)
|
2005-05-18 |
2014-06-21 |
Array Biopharma Inc |
Ｍｅｋ雜環抑制劑及其使用方法
|
|
NZ567140A
(en)
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
US7612212B2
(en)
|
2006-02-22 |
2009-11-03 |
Hoffmann-La Roche Inc. |
Substituted hydantoins
|
|
US20090239936A1
(en)
|
2006-05-15 |
2009-09-24 |
Yoshikazu Sugimoto |
Prophylactic and Therapeutic Agent for Cancer
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
DE602007011628D1
(de)
|
2006-07-06 |
2011-02-10 |
Array Biopharma Inc |
Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
|
|
RU2481336C2
(ru)
|
2006-07-06 |
2013-05-10 |
Эррэй Биофарма Инк. |
Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
|
|
WO2008006039A1
(en)
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Dihydrothieno pyrimidines as akt protein kinase inhibitors
|
|
EP1908751A1
(en)
*
|
2006-10-03 |
2008-04-09 |
EOS S.p.A. |
N-hydroxy benzamides with antitumour activity
|
|
MX2009004269A
(es)
|
2006-10-23 |
2009-08-12 |
Takeda Pharmaceutical |
Inhibidores de cinasa mapk/erk.
|
|
WO2008076415A1
(en)
|
2006-12-14 |
2008-06-26 |
Exelixis, Inc. |
Methods of using mek inhibitors
|
|
WO2008075741A1
(ja)
*
|
2006-12-20 |
2008-06-26 |
Keio University |
糖尿病治療剤及び予防剤
|
|
CA2692502C
(en)
|
2007-07-05 |
2016-03-01 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
MX2009014013A
(es)
|
2007-07-05 |
2010-01-28 |
Array Biopharma Inc |
Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
EP2188276B1
(en)
|
2007-08-16 |
2012-03-28 |
F. Hoffmann-La Roche AG |
Substituted hydantoins
|
|
CN101896469A
(zh)
|
2007-12-20 |
2010-11-24 |
霍夫曼-拉罗奇有限公司 |
作为mek激酶抑制剂的取代的乙内酰脲类化合物
|
|
US8853216B2
(en)
|
2008-01-09 |
2014-10-07 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
|
|
US8835434B2
(en)
|
2008-01-09 |
2014-09-16 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
WO2009143224A2
(en)
|
2008-05-20 |
2009-11-26 |
Fox Chase Center Center |
Method for the treatment or prophylaxis of lymphangioleiomyomatosis (lam) and animal model for use in lam research
|
|
AU2009279940B2
(en)
|
2008-08-04 |
2014-01-16 |
Merck Patent Gmbh |
Novel phenylamino isonicotinamide compounds
|
|
AR073216A1
(es)
|
2008-08-27 |
2010-10-20 |
Leo Pharma As |
Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos
|
|
EP2346818B1
(en)
|
2008-11-10 |
2012-12-05 |
Bayer Intellectual Property GmbH |
Substituted sulphonamido phenoxybenzamides
|
|
EP2370568B1
(en)
|
2008-12-10 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
CN102574782B
(zh)
|
2009-10-21 |
2014-10-08 |
拜耳知识产权有限责任公司 |
取代的卤代苯氧基苯甲酰胺衍生物
|
|
US8962606B2
(en)
|
2009-10-21 |
2015-02-24 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
CA2777430A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
CA2789696C
(en)
|
2010-02-25 |
2017-11-07 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
EP2545187B1
(en)
|
2010-03-09 |
2018-09-05 |
Dana-Farber Cancer Institute, Inc. |
Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
|
|
WO2012055953A1
(en)
|
2010-10-29 |
2012-05-03 |
Bayer Pharma Aktiengesellschaft |
Substituted phenoxypyridines
|
|
US9732319B2
(en)
|
2010-12-22 |
2017-08-15 |
Fate Therapeutics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
|
FI2694072T4
(fi)
|
2011-04-01 |
2024-09-30 |
Genentech Inc |
Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
|
|
TR201815685T4
(tr)
|
2011-04-01 |
2018-11-21 |
Genentech Inc |
Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
|
|
EP2714037B1
(en)
|
2011-05-25 |
2016-07-13 |
Université Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
CN103204825B
(zh)
|
2012-01-17 |
2015-03-04 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
|
|
WO2013169858A1
(en)
|
2012-05-08 |
2013-11-14 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
SI2909188T1
(en)
|
2012-10-12 |
2018-07-31 |
Exelixis, Inc. |
A novel process for the manufacture of compounds for use in the treatment of cancer
|
|
WO2015038704A1
(en)
|
2013-09-11 |
2015-03-19 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
|
WO2015108907A2
(en)
|
2014-01-14 |
2015-07-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
|
CN120536341A
(zh)
|
2014-03-04 |
2025-08-26 |
菲特治疗公司 |
改良的重编程方法和细胞培养平台
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
|
US10626372B1
(en)
|
2015-01-26 |
2020-04-21 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
CN117737124A
(zh)
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
|
CN122146606A
(zh)
|
2015-11-04 |
2026-06-05 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
|
US12642852B1
(en)
|
2015-11-04 |
2026-06-02 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
AU2017210031C1
(en)
|
2016-01-20 |
2020-11-26 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
KR20190070912A
(ko)
*
|
2016-07-28 |
2019-06-21 |
더 존스 홉킨스 유니버시티 |
O-치환된 히드록삼산
|
|
US11932870B2
(en)
|
2016-12-05 |
2024-03-19 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
CN107556201B
(zh)
*
|
2017-09-08 |
2020-10-27 |
山西智创药研科技有限公司 |
一种制备间氨基苯酚的工艺方法
|
|
WO2020106305A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
CN113660931B
(zh)
*
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
|
|
CA3129665A1
(en)
|
2019-03-21 |
2020-09-24 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
KR20220098759A
(ko)
|
2019-11-08 |
2022-07-12 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키나제 억제제에 대해 내성을 획득한 암의 치료 방법
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN117157065A
(zh)
|
2021-01-21 |
2023-12-01 |
恩福莱克逊治疗有限公司 |
吡咯并吡啶-苯胺化合物的晶型
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
EP4788839A1
(en)
|
2023-10-03 |
2026-08-12 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|